ZEN-3694 with platinum chemotherapy in NUT carcinoma (NCI phase 1/2)
The main open trial for NUT carcinoma, pairing a BET inhibitor that attacks the BRD4-NUT fusion directly with the platinum chemotherapy patients would otherwise receive alone.
Overview
NUT carcinoma is driven by a fusion of NUTM1 to BRD4 or another BET protein, so BET bromodomain inhibitors are its most rational drugs; single agents produced responses but not durable ones. This National Cancer Institute study tests ZEN003694 with platinum-based chemotherapy in advanced NUT carcinoma, with a dose-finding phase 1 leading into phase 2. It is recruiting.
Similar pages
not linked directly; found by shared links- TrialZEN-3694 with abemaciclib in NUT carcinoma, breast cancer and other solid tumours (NCI phase 1)
Shares ZEN-3694, NUT carcinoma (midline carcinoma with NUTM1 rearrangement), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), National Cancer Institute (NIH) and the tag owner-request.
- TrialCemiplimab in metastatic or unresectable NUT carcinoma (Northwestern pilot)
Shares NUT carcinoma (midline carcinoma with NUTM1 rearrangement) and the tag owner-request.
- TrialTIGER: standard-dose TIP versus high-dose TI-CE with stem cell transplant as first salvage for relapsed germ cell tumours
- TrialTazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in)
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag owner-request.
- TrialPembrolizumab with or without anetumab ravtansine in mesothelin-positive pleural mesothelioma (NCI)
Shares National Cancer Institute (NIH) and the tag owner-request.
- TreatmentAldoxorubicin
Shares Cytotoxic chemotherapy and the tag owner-request.
- TrialAldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma
Shares Cytotoxic chemotherapy and the tag owner-request.
- CompanyGemini Therapeutics
Shares Cytotoxic chemotherapy and the tag owner-request.